2/6
07:30 am
ymab
Y-mAbs to Present at the Oppenheimer 35?? Annual Life Sciences Conference
Low
Report
Y-mAbs to Present at the Oppenheimer 35?? Annual Life Sciences Conference
1/31
07:35 am
ymab
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
High
Report
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
1/13
08:04 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
1/10
08:13 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.
1/10
10:16 am
ymab
Y-mAbs Therapeutics guides FY2024 revenue below estimates [Seeking Alpha]
Medium
Report
Y-mAbs Therapeutics guides FY2024 revenue below estimates [Seeking Alpha]
1/10
09:26 am
ymab
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
Medium
Report
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
1/10
07:35 am
ymab
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
Low
Report
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
1/10
07:05 am
ymab
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Low
Report
Y-mAbs Provides Strategic Business Update and 2025 Priorities
12/23
07:37 am
ymab
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
12/23
07:30 am
ymab
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/20
09:04 am
ymab
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely [Yahoo! Finance]
12/11
08:21 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/7
12:06 pm
ymab
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting [Yahoo! Finance]
Low
Report
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting [Yahoo! Finance]
12/7
12:00 pm
ymab
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Low
Report
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
12/6
05:31 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
12/5
08:01 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $17.00 price target on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $17.00 price target on the stock.
11/27
07:35 am
ymab
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
Low
Report
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference